Chief Physician, Director for Hematology Department 1, and Director for the Medical Laboratory, who holds a Master's degree in Medicine from Tongji Medical University.

　　She has been engaged in clinical work for more than 30 years and experimental research in internal medicine，especially hematology. She had acted as a resident physician, attending physician, associate chief physician for Institute of Hematology, Deputy Director for the Department for Blood Transfusion and Deputy Director for Cell Therapy Center, Peking University People's Hospital. She had acted as Director for the Department of Hematology, Department of Immunotherapy and Special Center for Detection of Blood Diseases, Beijing Daopei Hospital. She had acted as Vice President for Hebei Yanda Ludaopei Hospital. She had stayed in the Affiliated Hospital of West China Medical University for further studies and been involved in an experimental study on blood tumor immunity in Stanford University Medical Center.

She specializes in the treatment of malignant tumors, especially immunotherapy for acute leukemia, and integrated diagnosis through hematological diseases, including cell morphology, cytochemistry, immunohistochemistry, flow cytometry, chromosome and fluorescence in situ hybridization (FISH), genetic diagnostic technologies, pathogen detection technologies, and techniques for analysis of drug concentrations and drug-metabolism genes to achieve integrated treatment and individualized treatment of blood diseases.

Currently she is a member of the Standing Committee of the Professional Committee for

Medical Biotechnology for Clinical application, China Medicinal Biotech Association, a member of the Professional Committee for Biological Therapy, China Anti-cancer Association, a member of the Professional Committee for Hematologic Oncology, China Anti-cancer Association, Deputy Director for the Professional Committee for Hematologic Oncology under the Laboratory Physician Branch, the Chinese Medical Doctor Association, Deputy Director for the Expert Committee for Blood Cell Testing in Beijing, and an editorial board member of the Chinese Journal of Biotherapy. She had acted as a drug review expert for the CFDA, a member of the Eighth National Pharmacopoeia Commission, a member of multiple sessions of the China Bone Marrow Library Expert Committee, and a member of “Expert Committee for Clinical Human Body Cell Research and In vitro Preparation Technology Management”, the Ministry of Health, an editorial board member of the Chinese Journal of Hematology, and a special expert for the project “Stem Cell Clinical Research and Industrialization” supported by the Fund for Major Science and Technology Projects in Beijing.

In 1992, Tong Chunrong was involved in "A study of the anti-tumor effect of cytokine-induced killer cells (CIK) in vitro and in animals" at the Stanford University Medical Center.

In 1996-1998, as an applicant, she received a grant for the project titled "Study of the in vitro purification and mechanism of cytokine-induced killer cells on chronic myelogenous leukemia cells" from the Ministry of Health.

In 1997, she was responsible for applying to the State Drug Administration (SDA) for the conduct of a clinical trial of the treatment with autologous CIK for acute leukemia and chronic viral hepatitis.

In 2000, she published the results of the clinical trial of the treatment with autologous CIK for acute leukemia and hepatitis C in the Journal of Beijing Medical University.

In 2002, she completed “A phase I clinical trial of the treatment with autologous CIK for acute leukemia”.

In 2002, she was responsible for reporting to SDA the results of “A phase I clinical trial of the treatment with autologous CIK for acute leukemia”.

In 2003, SDA approved the “phase II clinical trial of autologous CIK for the treatment of acute leukemia”.

As the deputy team leader of the mainland in 2002-2004, , she was awarded a grant for the project titled “Development of Techniques for the Diagnosis and Treatment of Leukemia” jointly sponsored by the National Natural Science Foundation of China and the Hong Kong Research Grants Council.

As the principal investigator in 2002-2004, she was awarded a grant by the Ministry of Education for the project titled "Mechanism of densus cells combined with cytokine-induced killer cells for the treatment of gastrointestinal malignancies and clinical studies".

As one of the responsible persons in 2007-2011, she was awarded a grant for the project titled “Function-specific lymphocyte infusion for the treatment of malignant tumors” supported by the Fund for the Major International Cooperation Projects sponsored by the Ministry of Science and Technology.

In 2009, the 51st ASH Conference was selected as a poster presentation.

In 2014, she was selected to attend the 76th Annual Meeting of the Japanese Society of Hematology (JSH) to deliver a speech on the approach to NK cell culture improved by the team led by her

In 2015, she led a team to work with Shanghai YaKe Biotech to use a new second-generation CD19-41BB-CART CAR-T cell to treat refractory and relapsed acute B lymphocytic leukemia.

In 2016, her paper issued at the European Hematology Association Meeting and the ASH Meeting, etc., was accepted and published by the internationally renowned magazine Leukemia.